ConductScience.org, home

Paper39152241

Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.

Parsa S and 4 others. Cardiol Ther, 2024. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Milvexian: An Oral, Bioavailable Factor XIa Inhibitor. Papers, record 39152241. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39152241

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.
PubMed
Journal
Cardiol Ther
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0.0, provisional
iCite
Revised in PubMed
2024-12-02
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Parsa SShyon
2Jain SSSneha S
3Akinrimisi OOlu
4Lam CSPCarolyn S P
5Mahaffey KWKenneth W

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136030390
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation2022https://conductscience.org/library/papers/36030390PubMed
225482425Factor XI antisense oligonucleotide for prevention of venous thrombosis.N Engl J Med2015https://conductscience.org/library/papers/25482425PubMed
330700128Intrinsic Pathway of Coagulation and Thrombosis.Arterioscler Thromb Vasc Biol2019https://conductscience.org/library/papers/30700128PubMed
434558200First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.Clin Transl Sci2022https://conductscience.org/library/papers/34558200PubMed
535647061Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence.Front Cardiovasc Med2022https://conductscience.org/library/papers/35647061PubMed
621870978Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med2011https://conductscience.org/library/papers/21870978PubMed
737285155Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation.JAMA Netw Open2023https://conductscience.org/library/papers/37285155PubMed
831935028Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.JAMA2020https://conductscience.org/library/papers/31935028PubMed
935385695
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Lancet2022https://conductscience.org/library/papers/35385695PubMed
1033471623Role of platelets in regulating activated coagulation factor XI activity.Am J Physiol Cell Physiol2021https://conductscience.org/library/papers/33471623PubMed
1137101592Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis.TH Open2023https://conductscience.org/library/papers/37101592PubMed
1236813377Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.J Am Coll Cardiol2023https://conductscience.org/library/papers/36813377PubMed
1319717844Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med2009https://conductscience.org/library/papers/19717844PubMed
1434985309Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.Circulation2022https://conductscience.org/library/papers/34985309PubMed
1522993391In vivo roles of factor XII.Blood2012https://conductscience.org/library/papers/22993391PubMed
1633541109Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.Circ Cardiovasc Qual Outcomes2021https://conductscience.org/library/papers/33541109PubMed
1734297496Abelacimab for Prevention of Venous Thromboembolism.N Engl J Med2021https://conductscience.org/library/papers/34297496PubMed
1834494428Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.J Med Chem2022https://conductscience.org/library/papers/34494428PubMed
1917258668Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack.Lancet2007https://conductscience.org/library/papers/17258668PubMed
2036063821Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.Lancet2022https://conductscience.org/library/papers/36063821PubMed

See all 42 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39152241

GET https://conductscience.org/api/papers/v1/39152241/references?page=2